---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-061322"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:57:36.161442+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Lantheus appoints Minnie Baylor-Henry to Board of Directors

## Summary
- Ms. Baylor-Henry, an expert in FDA regulatory affairs, appointed as Class II independent director effective March 1, 2022.
- Will serve on the Compensation Committee and Science and Technology Committee.
- Board now comprises nine directors, eight of whom are independent.
- Compensation includes $55,000/yr cash, $25,833 initial RSU grant, and $155,000 annual RSU grant.
- She previously served at FDA, Johnson & Johnson, and Deloitte; also on boards of APYX, PRTK, SCPH.

## SEC filing metadata
- accession: 0001193125-22-061322
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/0001193125-22-061322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/d299239d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-061322
- JSON: https://secwatch.observer/filing/0001193125-22-061322.json
- Plain text: https://secwatch.observer/filing/0001193125-22-061322.txt

## Key facts
- Executive change
  Minnie Baylor-Henry was appointed as Director at Lantheus Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 1, 2022, Lantheus Holdings, Inc. (“Lantheus”) appointed Ms. Minnie Baylor-Henry, a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312522061322/0001193125-22-061322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.